flow trial semaglutide kidney 2024 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators FLOW: Semaglutide Scores Big in
Description
If lower doses were effective, we would have studied them
The same principles apply to semaglutide left out overnight and tirzepatide that gets warm
Avoid taking the medication too early or doubling up on doses, as this can lead to complications
Furthermore, within six months of treatment, Wegovy reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due to heart failure
